Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

  1. Kalakonda, N.
  2. Maerevoet, M.
  3. Cavallo, F.
  4. Follows, G.
  5. Goy, A.
  6. Vermaat, J.S.P.
  7. Casasnovas, O.
  8. Hamad, N.
  9. Zijlstra, J.M.
  10. Bakhshi, S.
  11. Bouabdallah, R.
  12. Choquet, S.
  13. Gurion, R.
  14. Hill, B.
  15. Jaeger, U.
  16. Sancho, J.M.
  17. Schuster, M.
  18. Thieblemont, C.
  19. De la Cruz, F.
  20. Egyed, M.
  21. Mishra, S.
  22. Offner, F.
  23. Vassilakopoulos, T.P.
  24. Warzocha, K.
  25. McCarthy, D.
  26. Ma, X.
  27. Corona, K.
  28. Saint-Martin, J.-R.
  29. Chang, H.
  30. Landesman, Y.
  31. Joshi, A.
  32. Wang, H.
  33. Shah, J.
  34. Shacham, S.
  35. Kauffman, M.
  36. Van Den Neste, E.
  37. Canales, M.A.
  38. Show all authors +
Journal:
The Lancet Haematology

ISSN: 2352-3026

Year of publication: 2020

Volume: 7

Issue: 7

Pages: e511-e522

Type: Article

DOI: 10.1016/S2352-3026(20)30120-4 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus